Back to School: How biopharma can reboot drug development. Access exclusive analysis here

0811 ECP GentiBio
BioCentury & Getty Images

Emerging Company Profile

GentiBio: combining trio of platforms to enhance Treg therapies

Launches with $20M to engineer stable, tunable and tissue-specific Treg cell therapies

GentiBio debuts with a $20 million seed round to engineer stable, tunable and tissue-specific Treg cell therapies for autoimmune diseases.

Aug 11, 2020 | 11:00 PM GMT

GentiBio launched this summer with a suite of technologies to develop next-generation Treg cell therapies that overcome several of the modality’s historical shortcomings, including stability and specificity. The company, which

Read the full 834 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE